Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) was featured in a recent article that discussed its efforts to build a healthcare company focused on opportunities across the rapidly evolving peptide sector, combining proprietary therapeutic development, pharmaceutical-quality supply infrastructure and innovative drug delivery technologies. “As demand for solutions addressing metabolic health, muscle preservation, recovery and healthy ageing continues to grow, Adaptogenics is positioning itself to address significant healthcare challenges while pursuing opportunities in the expanding market for high-quality peptide development and supply,” the article reads. “The company’s strategy combines experienced pharmaceutical leadership, scientific innovation and a capital-efficient business model designed to create both near-term commercial opportunities and long-term value through proprietary therapeutic assets.”
To view the full article, visit https://ibn.fm/NAEye
About Adaptogenics Health Corp.
Adaptogenics is building a science led company focused on identifying, acquiring, designing and advancing proprietary peptide and small molecule programs. The company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The company will continue its existing nutraceutical operations while evaluating GLP 1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.
NOTE TO INVESTORS: The latest news and updates relating to ADPTare available in the company’s newsroom at https://ibn.fm/ADPT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
